Physicians' Academy for Cardiovascular Education

PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

Aug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona.

Video navigation menu

  • Similarities and differences in study design of the PCSK9 inhibition CV outcome trials and (expected) results 0:27
  • FOURIER: details on study design, baseline characteristics and results 3:17
  • Is it surprising that no reductio in CV death was seen during the FOURIER trial? 8:02
  • What can subgroup analyses tell us, including landmark analyses on those treated 2-3 years? 9:40
  • How do the FOURIER resuts compare to the CTTC observations 11:36
  • Additional insights on PCSK9 inhibition from the SPIRE 1&2 trials 14:51

Educational information

The educational objectives of the symposium were to:

CME Accreditation

This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Faculty

Peter Sever is Professor of Clinical Pharmacology and Therapeutics at Imperial College London and Honorary Consultant Physician at the Imperial College Healthcare NHS Trust. He is co-director of the International Centre for Circulatory Health and Head of the Physiology and Prevention Section of the National Heart and Lung Institute, Imperial College London.

Disclosures

This symposium was supported by unrestricted educational grant provided by Amgen and Sanofi-Regeneron

The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-CME.

View and download slides